Fate Therapeutics, Inc. (NasdaqGM:FATE) Stock Price & Quote Analysis

FATE Stock Overview

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.

FATE fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 6.7% below our estimate of its fair value

Risk Analysis

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

My Notes

New

Notes are coming soon

Fate Therapeutics, Inc. Competitors

Protagonist Therapeutics

NasdaqGM:PTGX

US$653.8m

Arbutus Biopharma

NasdaqGS:ABUS

US$474.1m

I-Mab

NasdaqGM:IMAB

US$500.3m

CTI BioPharma

NasdaqCM:CTIC

US$701.7m

Price History & Performance

Summary of all time highs, changes and price drops for Fate Therapeutics
Historical stock prices
Current Share Price	US$5.96
52 Week High	US$43.12
52 Week Low	US$4.02
Beta	1.62
1 Month Change	-40.93%
3 Month Change	-69.36%
1 Year Change	-84.95%
3 Year Change	-77.58%
5 Year Change	-25.87%
Change since IPO	-9.97%

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Jan 10

Recent updates

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Jan 10

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Sep 22

We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

Jun 02

We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Feb 01

Fate Therapeutics (NASDAQ:FATE) Is In A Good Position To Deliver On Growth Plans

Oct 16

Companies Like Fate Therapeutics (NASDAQ:FATE) Can Afford To Invest In Growth

Jul 18

This Is Why Fate Therapeutics, Inc.'s (NASDAQ:FATE) CEO Compensation Looks Appropriate

May 26

Companies Like Fate Therapeutics (NASDAQ:FATE) Can Afford To Invest In Growth

Apr 13

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 19

J. Wolchko Is The Founder of Fate Therapeutics, Inc. (NASDAQ:FATE) And They Just Sold 28% Of Their Shares

Jan 15

Companies Like Fate Therapeutics (NASDAQ:FATE) Can Afford To Invest In Growth

Jan 01

Shareholder Returns

	FATE	US Biotechs	US Market
7D	10.4%	-0.2%	1.7%
1Y	-84.9%	3.9%	-12.5%

Return vs Industry: FATE underperformed the US Biotechs industry which returned 1.2% over the past year.

Return vs Market: FATE underperformed the US Market which returned -13.6% over the past year.

Price Volatility

Is FATE's price volatile compared to industry and market?
FATE volatility
FATE Average Weekly Movement	21.7%
Biotechs Industry Average Movement	12.3%
Market Average Movement	6.9%
10% most volatile stocks in US Market	17.5%
10% least volatile stocks in US Market	2.8%

Stable Share Price: FATE is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: FATE's weekly volatility has increased from 15% to 22% over the past year.

About the Company

Founded	Employees	CEO	Website
2007	545	J. Wolchko	https://www.fatetherapeutics.com

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd.

Fate Therapeutics, Inc. Fundamentals Summary

How do Fate Therapeutics's earnings and revenue compare to its market cap?
FATE fundamental statistics
Market Cap	US$579.14m
Earnings (TTM)	-US$293.98m
Revenue (TTM)	US$69.01m

8.4x

P/S Ratio

-2.0x

P/E Ratio

Is FATE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
FATE income statement (TTM)
Revenue	US$69.01m
Cost of Revenue	US$12.99m
Gross Profit	US$56.03m
Other Expenses	US$350.01m
Earnings	-US$293.98m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-3.03
Gross Margin	81.18%
Net Profit Margin	-425.98%
Debt/Equity Ratio	0%

How did FATE perform over the long term?

See historical performance and comparison

FATE Stock Overview

Rewards

Risk Analysis

Fate Therapeutics, Inc. Competitors

NasdaqGM:PTGX

US$653.8m

NasdaqGS:ABUS

US$474.1m

NasdaqGM:IMAB

US$500.3m

NasdaqCM:CTIC

US$701.7m

Price History & Performance

Recent News & Updates

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc

Founder recently sold US$241k worth of stock

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Now 40% undervalued after recent price drop

Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, Effective as of March 6, 2023

Price target decreased to US$59.15

Recent updates

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc

Founder recently sold US$241k worth of stock

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Now 40% undervalued after recent price drop

Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, Effective as of March 6, 2023

Price target decreased to US$59.15

Price target decreased to US$61.10

Fate Therapeutics Announces Clinical Safety and Activity Data of First-Ever iPSC-Derived Car T-Cell Therapy

Insufficient new directors

Price target decreased to US$66.29

Third quarter 2022 earnings released: US$0.86 loss per share (vs US$0.45 loss in 3Q 2021)

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Chief Financial Officer recently sold US$153k worth of stock

Price target decreased to US$74.05

Consensus forecasts updated

Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8aß T Cells from TCR-CAR+ Induced Pluripotent Stem Cells

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Founder notifies of intention to sell stock

Chief Research & Development Officer exercised options and sold US$472k worth of stock

Chief Technical Officer recently sold US$92k worth of stock

Fate Therapeutics, Inc. Appoints Brian T. Powl as Chief Commercial Officer

General Counsel & Corporate Secretary exercised options and sold US$410k worth of stock

We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Founder notifies of intention to sell stock

Insufficient new directors

Fate Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Chief Medical Officer recently sold US$144k worth of stock

General Counsel & Corporate Secretary exercised options and sold US$841k worth of stock

Chief Research & Development Officer notifies of intention to sell stock

Consensus forecasts updated

Fate Therapeutics, Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Founder exercised options and sold US$1.5m worth of stock

Founder recently sold US$709k worth of stock

Fate Therapeutics Announces FDA Clearance for Ft536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors

General Counsel & Corporate Secretary exercised options and sold US$2.6m worth of stock

Chief Research & Development Officer notifies of intention to sell stock

Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting

Founder notifies of intention to sell stock

Third quarter 2021 earnings released: US$0.45 loss per share (vs US$0.68 loss in 3Q 2020)

Founder notifies of intention to sell stock

Fate Therapeutics (NASDAQ:FATE) Is In A Good Position To Deliver On Growth Plans

CFO & Principal Accounting Officer exercised options and sold US$468k worth of stock

Chief Research & Development Officer exercised options and sold US$1.6m worth of stock

Founder exercised options and sold US$1.7m worth of stock

CFO & Principal Accounting Officer recently sold US$307k worth of stock

Fate Therapeutics, Inc. Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-Shelf

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.58 loss per share (vs US$0.35 loss in 2Q 2020)

Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy

Founder notifies of intention to sell stock

Companies Like Fate Therapeutics (NASDAQ:FATE) Can Afford To Invest In Growth

General Counsel & Corporate Secretary notifies of intention to sell stock

Chief Scientific Officer Daniel Shoemaker has left the company

Chief Scientific Officer notifies of intention to sell stock

Fate Therapeutics Highlights Positive Interim Data from Its Phase 1 Study of Ft516 in Combination with Rituximab for B-Cell Lymphoma At 2021 Asco Annual Meeting